错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

ZEB1-mediated fibroblast polarization controls inflammation and sensitivity to immunotherapy in colorectal cancer

  • Constantin Menche,
  • Harald Schuhwerk,
  • Isabell Armstark,
  • Pooja Gupta,
  • Kathrin Fuchs,
  • Ruthger van Roey,
  • Mohammed H Mosa,
  • Anne Hartebrodt,
  • Yussuf Hajjaj,
  • Ana Clavel Ezquerra,
  • Manoj K Selvaraju,
  • Carol I Geppert,
  • Stefanie Bärthel,
  • Dieter Saur,
  • Florian R Greten,
  • Simone Brabletz,
  • David B Blumenthal,
  • Andreas Weigert,
  • Thomas Brabletz,
  • Henner F Farin,
  • Marc P Stemmler

摘要

The EMT-transcription factor ZEB1 is heterogeneously expressed in tumor cells and in cancer-associated fibroblasts (CAFs) in colorectal cancer (CRC). While ZEB1 in tumor cells regulates metastasis and therapy resistance, its role in CAFs is largely unknown. Combining fibroblast-specific Zeb1 deletion with immunocompetent mouse models of CRC, we observe that inflammation-driven tumorigenesis is accelerated, whereas invasion and metastasis in sporadic cancers are reduced. Single-cell transcriptomics, histological characterization, and in vitro modeling reveal a crucial role of ZEB1 in CAF polarization, promoting myofibroblastic features by restricting inflammatory activation. Zeb1 deficiency impairs collagen deposition and CAF barrier function but increases NFκB-mediated cytokine production, jointly promoting lymphocyte recruitment and immune checkpoint activation. Strikingly, the Zeb1-deficient CAF repertoire sensitizes to immune checkpoint inhibition, offering a therapeutic opportunity of targeting ZEB1 in CAFs and its usage as a prognostic biomarker. Collectively, we demonstrate that ZEB1-dependent plasticity of CAFs suppresses anti-tumor immunity and promotes metastasis.